Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $14.33.

Several analysts have recently weighed in on ALT shares. Leerink Partners started coverage on Altimmune in a report on Monday, June 22nd. They set an “outperform” rating and a $10.00 price objective on the stock. Wall Street Zen upgraded Altimmune from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Evercore reaffirmed an “outperform” rating on shares of Altimmune in a research report on Wednesday, September 23rd. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, September 21st.

Altimmune Stock Down 3.5%

NASDAQ ALT opened at $2.76 on Friday. Altimmune has a twelve month low of $2.56 and a twelve month high of $6.44. The stock has a market cap of $536.88 million, a PE ratio of -3.54 and a beta of 0.07. The firm has a 50-day simple moving average of $3.10 and a 200 day simple moving average of $3.05. The company has a debt-to-equity ratio of 0.07, a quick ratio of 26.78 and a current ratio of 26.78.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. On average, research analysts forecast that Altimmune will post -0.58 EPS for the current year.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently added to or reduced their stakes in ALT. Dimensional Fund Advisors LP raised its holdings in shares of Altimmune by 268.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock worth $3,221,000 after buying an additional 762,223 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Altimmune in the second quarter valued at $2,097,000. Bank of America Corp DE grew its position in Altimmune by 48.6% in the first quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock valued at $1,756,000 after acquiring an additional 186,420 shares during the period. Hennion & Walsh Asset Management Inc. raised its stake in Altimmune by 156.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock worth $1,575,000 after acquiring an additional 316,209 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Altimmune by 69.4% during the second quarter. Wellington Management Group LLP now owns 420,300 shares of the company’s stock worth $1,278,000 after acquiring an additional 172,142 shares in the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc is a clinical-stage biotechnology company focused on developing treatments for obesity and liver diseases. The company’s lead product candidate is pemvidutide, a dual GLP-1/glucagon receptor agonist being studied for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease associated with metabolic disorders.

Altimmune’s research programs are designed to address diseases with significant unmet medical needs, including obesity-related complications and conditions involving liver inflammation and fibrosis.